Gemita (Gemcitabine) 200mg Injection

A qualified oncology team administers it as an intravenous infusion, usually combined with other chemotherapy agents.

Gemita 200mg Injection Ingredients and Usage

Gemita 200mg Injection contains gemcitabine, a nucleoside analogue belonging to the antimetabolite anticancer drug class. Oncologists prescribe it as first line therapy for locally advanced or metastatic pancreatic cancer, often alone or combined with other agents.

Gemita 200mg Injection also treats non small cell lung cancer, metastatic breast cancer, recurrent ovarian cancer after platinum based therapy, and bladder cancer. It is typically given in combination with other chemotherapy drugs and administered in defined cycles under specialist supervision.

How Does Gemita 200mg Injection Work?

Gemcitabine mimics the natural nucleosides that cells use to build DNA. Once activated inside the cell, it gets incorporated into the growing DNA strand in place of a natural building block, which halts further DNA chain elongation.

Gemita 200mg Injection also inhibits ribonucleotide reductase, an enzyme cancer cells need to produce the raw materials for DNA synthesis. Together, these actions block DNA replication and cell division, causing cancer cells to die, particularly those with a high rate of division.

Gemita 200mg Injection Side Effects

Gemita 200mg Injection commonly causes blood count changes and flu-like side effects. Regular blood tests are used to monitor for these during treatment.

• Low white blood cell and platelet count

• Nausea and vomiting

• Fever

• Loss of appetite

• Hair loss or thinning

• Skin rash

• Swelling and redness at the injection site

Warnings

• Gemita 200mg Injection can cause hemolytic uremic syndrome, a serious and potentially fatal condition; kidney function must be assessed before starting treatment, and therapy should be stopped if signs of kidney injury appear.

• The medicine can cause liver injury, including fatal outcomes; liver function must be assessed before treatment, and therapy should be discontinued if signs of liver injury develop.

• Gemita 200mg Injection can cause severe lung injury, including pulmonary fibrosis and capillary leak syndrome; report any breathing difficulty immediately.

• Bone marrow suppression is common and can be severe; complete blood counts must be checked before each dose and monitored closely throughout treatment.

• Gemita 200mg Injection may impair male fertility; men should avoid fathering a child during treatment and for six months after the last dose, and effective contraception is required for both partners.

• Avoid live vaccines during treatment, since gemcitabine suppresses the immune system and increases infection risk.

• Report fever, chills, or any sign of infection between treatment cycles promptly, since myelosuppression increases vulnerability to serious infection.

Gemita 200mg Injection Storage Conditions

Store Gemita 200mg Injection at room temperature, following the specific storage instructions on the vial label. Keep the vial in its original packaging until immediately before use. Store this medicine out of reach of children and ensure only trained healthcare staff handle preparation and administration.